|
|
|
|
Spyre Therapeutics Inc (NASDAQ: SYRE) |
|
Price: $22.9200
$0.24 
1.058%
|
| Day's High:
| $23.19
| Week Perf:
| 0.75 %
|
| Day's Low: |
$ 22.43 |
30 Day Perf: |
5.82 % |
| Volume (M): |
462 |
52 Wk High: |
$ 47.97 |
| Volume (M$): |
$ 10,589 |
52 Wk Avg: |
$29.91 |
| Open: |
$22.78 |
52 Wk Low: |
$20.25 |
|
|
| Market Capitalization (Millions $) |
1,166 |
| Shares
Outstanding (Millions) |
51 |
| Employees |
36 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-215 |
| Cash Flow (TTM) (Millions $) |
-20 |
| Capital Exp. (TTM) (Millions $) |
0 |
Spyre Therapeutics Inc
Company Address: 221 Crescent Street Waltham 2453 MA
Company Phone Number: 651-5940 Stock Exchange / Ticker: NASDAQ SYRE
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Spyre Therapeutics Inc
As a Wall Street journalist, it is important to analyze the financial results of Spyre Therapeutics Inc in context of their recent stock performance.
For the financial interval closing March 31, 2024, Spyre Therapeutics Inc reported a net loss of $-1.20 per share, an improvement from the previous year's loss of $-5.00 per share. However, this was still a decline from the preceding financial reporting period when the company reported $0.00 per share. The revenue for the period remained unchanged at $0.00 million, compared to $0.20 million in the same period a year ago.
The company also realized a net shortfall of $-43.857 million for the period, which was larger than the $-18.422 million reported a year ago. Despite these financial challenges, the stock of Spyre Therapeutics Inc experienced a decline of -2.51% in the month of May, bringing the share price down by -10.76% during the second quarter of 2024.
Furthermore, the stock is currently trading only 5.6% above its 52-week low, indicating ongoing downward pressure on the share price. Investors may be concerned about the company's financial performance and its ability to generate revenue and profits in the future.
|
| Spyre Therapeutics Inc
The financial results of Spyre Therapeutics Inc for the fourth quarter of 2023 have unveiled a mixed bag of outcomes. Notably, the company experienced a significant improvement in net deficit, reporting a deficit of $0.000 million compared to $-18.822 million in the same quarter of the previous year. However, the revenue remained stagnant at $0.00 million, both year-on-year and sequentially. These financial figures raise questions about the future prospects of Spyre Therapeutics Inc and how the company may be affected moving forward.
1. Improvement in Net Deficit:
One positive aspect of the financial results is that Spyre Therapeutics Inc managed to reduce its net deficit significantly. In the fourth quarter of 2023, the company reported a mere $0.000 million deficit compared to a considerable deficit of $-18.822 million in the previous year. This improvement suggests that the company has implemented measures to control its expenses, leading to a more efficient financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.52 $ |
| Revenues (TTM) |
0 $
|
| Cash Flow (TTM) |
- |
| Cash |
8.14 $
|
| Book Value |
6.43 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.52 $
|
| Revenues (TTM) |
0 $ |
| Cash Flow (TTM) |
- |
| Cash |
8.14 $
|
| Book Value |
6.43 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
1.33% 